In Brief: Organic Guidance; NAD Review; FTC Enforcement; FDA Warning
This article was originally published in The Tan Sheet
Executive Summary
USDA organic guidance; NAD challenges Akeso’s “doctor recommended” claims; new name for NCCAM proposed; FTC finalizes decree with GeneLink; Fortune Hi-Tech Marketing resolves pyramid allegations; CDJ supplements are unapproved new drugs; more news In Brief.
You may also be interested in...
In Brief: laxatives warning, FTC settlement, ChromaDex inks 5LINX deal
Sodium phosphate laxatives linked to SAERs; FTC scrutinizes personalized supplement claims; NAD refers Xlear LLC to FTC; ChromaDex inks marketing deal with 5LINX; CVS launches vitamin sales, info hub on its website; Star Scientific shareholder suit proceeds.
Fortune Hi-Tech Complaint Could Intensify Scrutiny Of Multilevel Marketers
FTC worked with state authorities in an investigation of multilevel marketer Fortune Hi-Tech that led to a court order shutting down the firm. Meanwhile, nutritional and cosmetic product firm Nu Skin offers a defense against criticism of the multilevel business model after investors target Herbalife.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”